Chemed (NYSE:CHE) Releases FY24 Earnings Guidance

Chemed (NYSE:CHEGet Free Report) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $23.00-$23.15 for the period, compared to the consensus estimate of $23.58.

Chemed Price Performance

Shares of NYSE:CHE traded up $0.95 during trading on Tuesday, reaching $609.80. 93,980 shares of the stock were exchanged, compared to its average volume of 83,505. The stock has a fifty day moving average of $586.88 and a two-hundred day moving average of $569.34. Chemed has a 1-year low of $525.36 and a 1-year high of $654.62. The firm has a market cap of $9.23 billion, a price-to-earnings ratio of 32.77, a price-to-earnings-growth ratio of 2.44 and a beta of 0.44.

Chemed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 12th were issued a dividend of $0.50 per share. This is a boost from Chemed’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Monday, August 12th. Chemed’s dividend payout ratio (DPR) is currently 10.76%.

Insider Buying and Selling

In other Chemed news, Director George J. Walsh III sold 400 shares of Chemed stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $597.47, for a total transaction of $238,988.00. Following the completion of the transaction, the director now owns 3,046 shares in the company, valued at approximately $1,819,893.62. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Chemed news, Director George J. Walsh III sold 400 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the completion of the transaction, the director now owns 3,046 shares in the company, valued at $1,819,893.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the completion of the transaction, the chief executive officer now directly owns 105,735 shares in the company, valued at $60,229,828.05. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,144 shares of company stock worth $4,141,679 in the last quarter. Insiders own 3.32% of the company’s stock.

About Chemed

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

See Also

Earnings History and Estimates for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.